Clinical Trials Logo

Nonalcoholic Steatohepatitis clinical trials

View clinical trials related to Nonalcoholic Steatohepatitis.

Filter by:

NCT ID: NCT05211284 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US

SARONAPLUS
Start date: September 26, 2022
Phase: Phase 2
Study type: Interventional

Saroglitazar Magnesium 4 mg for NASH in People Living with HIV in the US

NCT ID: NCT05165706 Recruiting - Obesity Clinical Trials

Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance

Start date: January 31, 2019
Phase: N/A
Study type: Interventional

This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. Additionally, direct insulin sensitivity testing, and radiological measurement of visceral fat and intrahepatic fat content is measured at three timepoints to correlate clinical indices with cellular changes.

NCT ID: NCT05083390 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Norursodeoxycholic Acid vs. Placebo in NASH

Start date: July 8, 2019
Phase: Phase 2
Study type: Interventional

This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb trial. The trial will be conducted with three treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with either 1500 mg/d or 1000 mg/d norUDCA tablets vs. placebo tablets for the treatment of NASH.

NCT ID: NCT05029583 Recruiting - Type 2 Diabetes Clinical Trials

Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)

Start date: August 11, 2021
Phase: N/A
Study type: Interventional

The study is stratified cluster randomized trial. The study population will include adults with T2D and presumed NASH.

NCT ID: NCT05012423 Recruiting - Osteoarthritis Clinical Trials

FTIH Study of ECC0509 in Healthy Volunteers

Start date: July 7, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

NCT ID: NCT05011305 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

NASH
Start date: August 18, 2021
Phase: Phase 2
Study type: Interventional

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis

NCT ID: NCT04801849 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Vitamin E Dosing Study

VEDS
Start date: August 5, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).

NCT ID: NCT04710524 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Start date: June 10, 2021
Phase: Phase 2
Study type: Interventional

A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

NCT ID: NCT04550481 Recruiting - Clinical trials for Hepatocellular Carcinoma

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Start date: May 11, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver cancer. Liver fibrosis is the common finding of chronic liver diseases leading to reduced liver function. Lisinopril is a medication that is commonly used to treat high blood pressure. Lisinopril may help to decrease liver fibrosis. The purpose of this trial is to find out what effect, if any, lisinopril has on a patient's risk of developing liver cancer.

NCT ID: NCT04501406 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).